← FDA DRUG APPROVALS

FDA ANDA · ANDA085173

CHLOROTHIAZIDE

Sponsor: WATSON LABS

APPLICATION
ANDA085173
TYPE
ANDA
ORIGINAL APPROVAL
1977-11-04
LATEST ACTION
1996-03-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CHLOROTHIAZIDEDiscontinued
CHLOROTHIAZIDE 250MG · TABLET · ORAL

Approval history

1996-03-26Labeling · Supplement 29AP
1995-04-13Labeling · Supplement 28AP
1994-08-15Labeling · Supplement 27AP
1991-03-26Manufacturing (CMC) · Supplement 25AP
1991-01-28Manufacturing (CMC) · Supplement 26AP
1989-02-13Manufacturing (CMC) · Supplement 23AP
1989-02-13Manufacturing (CMC) · Supplement 22AP
1988-11-23Labeling · Supplement 21AP
1985-11-27Manufacturing (CMC) · Supplement 17AP
1985-11-27Manufacturing (CMC) · Supplement 18AP
1977-11-04OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →